MedTrace Logo

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

NCT00936962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2015-07-15

No results posted yet for this study

Summary

The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal C disease and to see if a booster vaccination is needed.

Conditions

  • Meningococcal Sero-type C Infection

Interventions

BIOLOGICAL

NeisVac C vaccine (12mth)

NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Julie Bettinger, Ph.D · University of British Columbia

  • David Scheifele, Ph.D · University of British Columbia

  • Scott Halperin, Ph.D · Dalhousie University, Halifax

  • James Kellner, Ph.D · University of Calgary

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
13 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936962 on ClinicalTrials.gov